鞘氨醇激酶-2在大颗粒淋巴细胞白血病中过表达并通过Mcl-1促进存活
该研究探讨鞘氨醇激酶-2(SPHK2)在大颗粒淋巴细胞(LGL)白血病中的表达及功能。多数LGL白血病患者样本中SPHK2 mRNA和蛋白上调,siRNA敲低或特异性抑制剂(ABC294640、K145)可降低LGL细胞系活力,ABC294640选择性诱导患者LGL细胞凋亡,机制涉及蛋白酶体降解下调Mcl-1。靶向SPHK2可能为LGL白血病提供新治疗策略。
要点
- SPHK2在多数LGL白血病患者样本中mRNA和蛋白上调
- SPHK2抑制剂ABC294640和K145降低LGL细胞系活力
- ABC294640选择性诱导患者LGL细胞凋亡并下调Mcl-1蛋白
核心结论
- SPHK2在LGL白血病中过表达并通过Mcl-1促进细胞存活,靶向SPHK2提供潜在治疗新策略。
研究设计与样本
- 实验研究:检测LGL白血病患者样本中SPHK2表达,并在LGL细胞系及患者原代细胞中进行功能验证。
主要发现
- 多数LGL白血病患者样本中SPHK2 mRNA和蛋白表达上调。
- siRNA敲低SPHK2降低LGL白血病细胞系增殖。
- SPHK2特异性抑制剂ABC294640或K145降低LGL白血病细胞系活力。
- ABC294640选择性诱导LGL细胞系及新鲜分离的LGL白血病患者细胞凋亡,对照正常细胞不受影响。
- SPHK2抑制通过蛋白酶体降解途径下调抗凋亡蛋白Mcl-1。
临床怎么用
- 靶向SPHK2(如ABC294640)可能成为LGL白血病的潜在治疗选择,需进一步临床验证。
局限性
- 研究主要基于体外细胞系和患者样本,缺乏体内模型及临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sphingolipid metabolism is increasingly recognised as a therapeutic target in cancer due to its regulation of cell proliferation and apoptosis. The sphingolipid rheostat is proposed to control cell fate through maintaining balance between pro-apoptotic and pro-survival sphingolipids. This balance is regulated by metabolising enzymes involved in sphingolipid production. One such enzyme, sphingosine kinase-2 (SPHK2), produces pro-survival sphingosine 1-phosphate (S1P) by phosphorylation of pro-apoptotic sphingosine. Elevated SPHK2 has been found in multiple cancer types and contributes to cell survival, chemotherapeutic resistance and apoptosis resistance. We have previously shown elevation of S1P in large granular lymphocyte (LGL) leukaemia serum and cells isolated from patients. Here, we examined SPHK2 expression in LGL leukaemia and found SPHK2 mRNA and protein upregulation in a majority of LGL leukaemia patient samples. Knockdown of SPHK2 with siRNA in LGL leukaemia cell lines decreased proliferation. Additionally, the use of ABC294640 or K145, both SPHK2-specific inhibitors, decreased viability of LGL leukaemia cell lines. ABC294640 selectively induced apoptosis in LGL cell lines and freshly isolated LGL leukaemia patient cells compared to normal controls. Mechanistically, SPHK2 inhibition downregulated pro-survival myeloid cell leukaemia-1 (Mcl-1) protein through proteasomal degradation. Targeting of SPHK2 therefore provides a novel therapeutic approach for the treatment of LGL leukaemia.
引用
- LeBlanc FR, Pearson JM, Tan SF, et al. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1. Br J Haematol. 2020. PMID: 32124438. doi:10.1111/bjh.16530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。